According to the study published in The BMJ journal, non-steroidal anti-inflammatory drugs (NSAIDs) to treat pain and inflammation could be raising risk of having a heart attack as early as in the first week of use and especially within the first month of taking high doses of such medication.
Previous studies suggested that NSAIDs could increase the risk of heart attack, but the timing of the risk, the effect of dose, treatment duration, and the comparative risks between NSAIDs were poorly understood.
They carried out a review of relevant studies from various healthcare databases including those from Canada, Finland and the UK.
They analysed results on 446,763 people of whom 61,460 had a heart attack.
The NSAIDs of interest to the researchers were celecoxib, the three main traditional NSAIDs (diclofenac, ibuprofen, and naproxen), and rofecoxib.
Researchers presented their results as probabilities of having a heart attack. They looked at various scenarios corresponding to how people might routinely use these drugs.
Naproxen was associated with the same risk of heart attack as that documented for other NSAIDs. With celecoxib, the risk was lower than for rofecoxib and was comparable to that of traditional NSAIDs.
Overall the increase in risk of a heart attack is about 20 to 50 per cent if using NSAIDs compared with not using these medications.
To put this in perspective, as a result of this increase, the risk of heart attack due to NSAIDs is on average about one per cent annually.
Further analysis suggested that the risk of heart attack associated with NSAID use was greatest with higher doses and during the first month of use.
With longer treatment duration, risk did not seem to continue to increase but the researchers caution that they did not study repeat heart attacks such that it remains prudent to use NSAIDs for as short time as possible.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
